[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM, European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol; 2010 Apr 01;28(10):1772-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
  • PURPOSE: Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma typically carrying a translocation between chromosomes 17 and 22 that generates functional platelet-derived growth factor B (PDGFB).
  • PATIENTS AND METHODS: Two distinct phase II trials of imatinib (400 to 800 mg daily) in patients with locally advanced or metastatic DFSP were conducted and closed prematurely, one in Europe (European Organisation for Research and Treatment of Cancer [EORTC]) with 14-week progression-free rate as the primary end point and the other in North America (Southwest Oncology Group [SWOG]) with confirmed objective response rate as the primary end point.
  • Median time to progression (TTP) was 1.7 years.
  • Median overall survival (OS) time has not been reached; 1-year OS rate was 87.5%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatofibrosarcoma / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Clinical Trials, Phase II as Topic. Drug Administration Schedule. Early Termination of Clinical Trials. Female. Humans. Imatinib Mesylate. Male. Middle Aged

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1999 Nov;72(3):178-80 [10562366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):690-5 [16407111.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2711-20 [10870053.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Oct;295(1):139-45 [10991971.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):696-704 [11034249.001]
  • [Cites] J Mol Diagn. 2000 Feb;2(1):47-52 [11272901.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):354-60 [11291071.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2965-75 [11420709.001]
  • [Cites] Cytogenet Cell Genet. 2001;92(3-4):192-5 [11435686.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5778-83 [11479215.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3586-91 [12202658.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):623-6 [12209598.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):27-39 [12502925.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):1-12 [12550751.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1118-22 [14597453.001]
  • [Cites] Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2072-6 [14606355.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2383-95 [14633610.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1008-16 [14983497.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):341-5 [15028319.001]
  • [Cites] Ann Surg Oncol. 2004 Apr;11(4):438-44 [15070606.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 6):30-6 [15176002.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):235-7 [15270901.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Arch Otolaryngol. 1984 Jun;110(6):398-404 [6721783.001]
  • [Cites] Surg Gynecol Obstet. 1986 May;162(5):449-52 [3704900.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2154-61 [2804904.001]
  • [Cites] CA Cancer J Clin. 1992 Mar-Apr;42(2):116-25 [1540852.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):241-8 [1607035.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Aug;76(1):1-9 [8076341.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2400-3 [7757993.001]
  • [Cites] Int J Dermatol. 1995 Apr;34(4):256-60 [7790140.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1553-8 [7495279.001]
  • [Cites] Dermatol Surg. 1996 Jun;22(6):530-4 [8646467.001]
  • [Cites] J Am Acad Dermatol. 1996 Jul;35(1):82-7 [8682970.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 15;89(2):175-6 [8697429.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2365-9 [8708729.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Jan;15(1):73-5 [8824728.001]
  • [Cites] Cytogenet Cell Genet. 1996;72(2-3):171-4 [8978765.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):600-13 [9344201.001]
  • [Cites] Eur J Cancer. 1997 Jun;33(7):1055-60 [9376187.001]
  • [Cites] Am J Dermatopathol. 1997 Dec;19(6):562-7 [9415611.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):823-7 [9531366.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):576-87 [9591728.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):187-93 [9739023.001]
  • [Cites] Oncogene. 1998 Sep 10;17(10):1313-9 [9771975.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3719-23 [10446987.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2113-20 [17468914.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):184-93 [17950782.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):821-2 [18296418.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1757-9 [18375907.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2717-25 [18451237.001]
  • [Cites] Clin Cancer Res. 2010 Jun 15;16(12):3288-95 [20439456.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2503-8 [15503305.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):866-73 [15681532.001]
  • [Cites] Anticancer Drugs. 2005 Apr;16(4):461-6 [15746584.001]
  • [Cites] Pediatr Blood Cancer. 2005 May;44(5):511-5 [15503291.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7669-75 [16234529.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • (PMID = 20194851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / CA42777
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Other-IDs] NLM/ PMC3040044
  •  go-up   go-down


2. Cassier PA, Dufresne A, El Sayadi H, Pissaloux D, Alberti L, Decouvelaere AV, Ranchere D, Ray-Coquard I, Blay JY: [Targeted therapy of sarcomas]. Bull Cancer; 2008 Oct;95(10):963-74
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Targeted therapy of sarcomas].
  • [Transliterated title] Traitement ciblé des sarcomes.
  • Soft tissue sarcomas can be divided into 6 sub-types based on the underlying molecular biology of the disease:.
  • 1) translocation leading to fusion proteins involving transcription factors or growth factors (Ewing sarcoma, myxoid liposarcoma, dermatofibrosarcoma protuberans);.
  • 3) tumor-suppressor gene deletion (type 1 neurofibromatosis, rhabdoid tumors);.
  • Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma.
  • [MeSH-major] Gastrointestinal Stromal Tumors / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Humans. Protein Kinase Inhibitors / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004727.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors
  •  go-up   go-down


3. Sanmartín O, Llombart B, López-Guerrero JA, Serra C, Requena C, Guillén C: [Dermatofibrosarcoma protuberans]. Actas Dermosifiliogr; 2007 Mar;98(2):77-87
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dermatofibrosarcoma protuberans].
  • [Transliterated title] Dermatofibrosarcoma protuberans.
  • Dermatofibrosarcoma protuberans (DFSP) is a soft tissue neoplasm of intermediate malignancy that is initially localized to the skin from where it can invade deep structures (fat, fascia, muscle and bone).
  • It is the most frequent fibrohistiocytic tumor, comprising approximately 1.8 % of all soft tissue sarcomas and 0.1 % of all cancers.
  • Treatment of localized disease consists in complete surgical excision of the lesion by conventional surgery with wide margins (>3 cm) or by micrographic Mohs surgery.
  • The prognosis for metastatic cases is very poor with a survival of less than 2 years following detection of metastatic disease.
  • Patients with locally advanced DFSP are not candidates for an initial radical surgical therapy therefore neoadyuvant treatment is required prior to surgery in order to reduce tumor burden.
  • In this regard, chemotherapy and radiotherapy have not been highly efficacious so it is necessary to consider new alternatives.
  • The demonstration of the oncogenic power of the translocation COL1A1-PDGFB in DFSP has allowed the successful introduction of drug therapy with antagonists of the PDGFB receptor for metastatic or locally advanced cases.
  • [MeSH-minor] Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 17 / ultrastructure. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 22 / ultrastructure. Combined Modality Therapy. Dermatofibrosarcoma / chemistry. Dermatofibrosarcoma / classification. Dermatofibrosarcoma / drug therapy. Dermatofibrosarcoma / genetics. Dermatofibrosarcoma / pathology. Dermatofibrosarcoma / surgery. Drug Design. Humans. Imatinib Mesylate. Mohs Surgery. Neoadjuvant Therapy. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Neoplasm Recurrence, Local. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Piperazines / therapeutic use. Prognosis. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor beta / antagonists & inhibitors. Ring Chromosomes. Sarcoma / chemistry. Sarcoma / drug therapy. Sarcoma / genetics. Sarcoma / pathology. Sarcoma / surgery. Translocation, Genetic

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17397592.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / COLIA1-PDGFB fusion protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Number-of-references] 68
  •  go-up   go-down


Advertisement
4. Mátrai Z, Liszkay G, Plotár V, Orosz Z, Székely J, Hitre E, Bartal A, Langmár Z, Bocs K, Rényi Vámos F, Sávolt A, Tóth L: [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans]. Orv Hetil; 2009 Oct 11;150(41):1894-902
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
  • [Transliterated title] Dermatofibrosarcoma protuberans multidiszciplináris kezelésével szerzett hosszú távú eredmények 26 betegnél.
  • Dermatofibrosarcoma protuberans is a low or moderate grade malignant, uncommon soft tissue tumor.
  • Initial treatment is the radical surgical excision, using traditional wide excision or Mohs surgery.
  • In case of positive surgical margin or local recurrence, radio-chemotherapy and recently imatinib mesylate is used as adjuvant therapy.
  • AIMS: Twenty-six patients treated multidisciplinary for dermatofibrosarcoma protuberans were followed up.
  • METHODS AND RESULTS: Mean age of the patients was 44.7 years; mean follow-up time was 60.57 months.
  • Six patients (23%) received adjuvant radiotherapy and two patients (7.6%) adjuvant chemotherapy following the removal of the primary tumor.
  • Ongoing treatments were needed in the case of ten patients (38.4%) who developed local recurrence.
  • CONCLUSIONS: Dermatofibrosarcoma protuberans can be successfully treated with multidisciplinary therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatofibrosarcoma / therapy. Mohs Surgery. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Benzamides. Chemotherapy, Adjuvant. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Piperazines / administration & dosage. Pyrimidines / administration & dosage. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801356.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


5. Han A, Chen EH, Niedt G, Sherman W, Ratner D: Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol; 2009 Jul;145(7):792-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
  • BACKGROUND: Dermatofibrosarcoma protuberans (DFSP) is an unusual soft-tissue tumor with a propensity for subclinical extension and local recurrence.
  • Surgical excision, even with tissue-sparing techniques, may cause significant deformity or disability because of the infiltrative nature of DFSP.
  • In this study, we evaluate retrospective data obtained from 4 patients with locally advanced or recurrent DFSP who received neoadjuvant imatinib mesylate therapy before undergoing Mohs micrographic surgery.
  • OBSERVATIONS: Patients treated with neoadjuvant imatinib therapy had an average tumor size reduction of 36.9%.
  • Imatinib therapy for DFSP before Mohs micrographic surgery was associated with 100% local control at a maximum follow-up of 4 years.
  • CONCLUSIONS: Neoadjuvant imatinib therapy is a well-tolerated, novel approach to DFSP that reduces tumor burden and facilitates resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatofibrosarcoma / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Neoadjuvant Therapy. Retrospective Studies

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620561.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


6. Kopp HG, Patel S, Brücher B, Hartmann JT: Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am J Clin Dermatol; 2008;9(4):207-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
  • Soft-tissue sarcomas (STS) include a spectrum of histologically and clinically different tumors.
  • Patients with these tumors are typically relatively young and the course of disease is characterized by early metastasis as well as limited response to chemotherapy.
  • However, a few subtypes, such as small round-cell tumors and rhabdomyosarcoma (other than pleomorphic), are considered chemotherapy sensitive.
  • In addition, reflecting successful translational research of recent years, gastrointestinal stromal tumor and dermatofibrosarcoma protuberans have become model diseases for targeted oncologic therapy.
  • We summarize current treatment options for metastatic STS, including established first-line chemotherapy approaches, mainly with anthracyclines and/or ifosfamide and second-line treatment choices beyond anthracyclines.
  • Until only a few years ago, treatment choices for metastatic STS were easy to review because of the very limited number of active compounds available.
  • However, with the advent of novel therapeutic strategies such as the anti-angiogenic approach and a multitude of novel compounds available both outside and within clinical studies, it has potentially become more difficult to keep track of currently available treatment options for STS and their clinical safety and efficacy.
  • In this practice-oriented article, we therefore review treatment goals in advanced STS and provide an overview of compounds with proven activity in this setting.
  • There is no evidence-based recommendation regarding use of second-line treatment options.
  • Recently, trabectedin, a DNA minor groove binder initially isolated from a sea sponge, has proven effective and received European approval for use in treatment-refractory STS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18572972.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 108
  •  go-up   go-down


7. Abe T, Kamida T, Goda M, Inoue R, Fujiki M, Kobayashi H, Hatano Y, Shibuya H, Fujiwara S, Terashi H, Mori T: Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans. J Clin Neurosci; 2009 Oct;16(10):1358-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial infiltration by recurrent scalp dermatofibrosarcoma protuberans.
  • Dermatofibrosarcoma protuberans (DFSP) of the scalp is a rare soft tissue sarcoma.
  • Despite this, there were several recurrences; thereafter, the patient underwent surgery, stereotactic radiosurgery and chemotherapy.
  • [MeSH-major] Dermatofibrosarcoma / surgery. Neoplasm Recurrence, Local / surgery. Scalp / pathology. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560926.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


8. Maki RG: Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther; 2004 Apr;4(2):229-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of chemotherapy in patients with soft tissue sarcomas.
  • The management of soft tissue sarcomas has been highlighted in the last few years by the responsiveness of gastrointestinal stromal tumors to imatinib (Gleevec, Novartis).
  • In this article, the use of chemotherapeutic agents in the management of this and some of the 50 or more subtypes of sarcomas are discussed, and a brief review of the use of chemotherapy in the adjuvant or neoadjuvant setting for people with large extremity sarcomas is provided.
  • Doxorubicin and ifosfamide (Mitoxana, Bristol-Myers Squibb) remain the best individual drugs for sarcomas overall, although dacarbazine and gemcitabine (Gemzar, Eli Lilly) with or without a taxane has activity in at least a subset of sarcomas.
  • The data regarding adjuvant chemotherapy for extremity soft tissue sarcomas is still quite mixed, with little if any overall survival advantage found to support its incorporation into disease management.
  • The finding of tyrosine kinase inhibitors such as imatinib with demonstrated activity in gastrointestinal stromal tumors and dermatofibrosarcoma protuberans, as well as the finding of new agents such as ecteinascidin-743 (Yondelis, PharmaMar) with at least some activity against soft tissue sarcomas, reinforces the idea that we should target individual subtypes of sarcoma, just as treatment varies by subtype for the hematological malignancies.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoadjuvant Therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15056053.001).
  • [ISSN] 1473-7140
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


9. Johnson-Jahangir H, Sherman W, Ratner D: Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. J Natl Compr Canc Netw; 2010 Aug;8(8):881-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses.
  • Dermatofibrosarcoma protuberans (DFSP) is an uncommon, low grade soft-tissue malignancy associated with a high risk for local recurrence and widespread subclinical extension.
  • Imatinib, a selective tyrosine kinase inhibitor, has been a beneficial adjuvant therapy in patients with unresectable, recurrent, or metastatic DFSP.
  • In recent cases, neoadjuvant imatinib mesylate therapy has been shown to reduce preoperative tumor size and lessen surgical morbidity associated with the removal of residual DFSP.
  • Use of neoadjuvant imatinib before surgery, however, requires appropriate patient selection and careful weighing of the potential risks and benefits of this treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatofibrosarcoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Humans. Imatinib Mesylate. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20870634.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


10. Gooskens SL, Oranje AP, van Adrichem LN, de Waard-van der Spek FB, den Hollander JC, van de Ven CP, van den Heuvel-Eibrink MM: Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer; 2010 Aug;55(2):369-73
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
  • Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children.
  • DFSP is characterized by a specific fusion of the platelet-derived growth factor beta (PDGFbeta) with the collagen type 1alpha1 (COL1alpha1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults.
  • In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome.
  • [MeSH-major] Dermatofibrosarcoma / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adolescent. Antineoplastic Agents. Benzamides. Child, Preschool. Humans. Imatinib Mesylate. Infant. Male. Protein Kinase Inhibitors. Remission Induction / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582941.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 16
  •  go-up   go-down


11. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Ruiz-Tovar J, Fernández Guarino M, Reguero Callejas ME, Aguilera Velardo A, Arano Bermejo J, Cabañas Navarro L: Dermatofibrosarcoma protuberans: review of 20-years experience. Clin Transl Oncol; 2006 Aug;8(8):606-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibrosarcoma protuberans: review of 20-years experience.
  • INTRODUCTION: Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue neoplasm with low-intermediate grade of malignancy.
  • Surgical excision with adequate margins is the main treatment.
  • Chemotherapy could be indicated in metastasic cases.
  • [MeSH-major] Dermatofibrosarcoma / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jun 15;88(12):2711-20 [10870053.001]
  • [Cites] Anticancer Drugs. 2005 Apr;16(4):461-6 [15746584.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2503-8 [15503305.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):392-7 [10419710.001]
  • [Cites] Eur J Surg Oncol. 1992 Jun;18(3):241-8 [1607035.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17 ):3586-91 [12202658.001]
  • [Cites] J Am Acad Dermatol. 1996 Sep;35(3 Pt 1):355-74; quiz 375-6 [8784271.001]
  • [Cites] Am J Dermatopathol. 1993 Oct;15(5):429-34 [7694515.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):823-7 [9531366.001]
  • (PMID = 16952850.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Macapinlac M, Elrafei T, Cunningham I, Horowitz M, Fauzia P, Mbaoma R, Jayabalan D, Mani S: Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response. J Clin Oncol; 2004 Jul 15;22(14_suppl):9049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatofibrosarcoma protuberans: Neoadjuvant therapy with imatinib mesylate and use of plasma PDGF-B levels to monitor clinical response.
  • : 9049 Background: Dermatofibrosarcoma protuberance (DFSP) is a rare soft tissue sarcoma; most cases show t(17:22) resulting in a COL1A1-PDGF-B fusion protein.
  • Imatinib mesylate, a known inhibitor of the PDGF receptor tyrosine kinase, has produced responses in some patients with chemotherapy-resistant locally advanced or metastatic DFSP.
  • Wide surgical excision of the tumor is still the accepted treatment despite local recurrence rate of 20-50% in completely resected patients.
  • CONCLUSIONS: This case shows the potential use of imatinib as neoadjuvant treatment in DFSP, and the potential value of measuring serial PDGF-B levels as a novel tumor marker not only in DFSP but perhaps in all tumors that depend on the PDGF-B pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014126.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED: Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs; 2005 Apr;16(4):461-6
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.
  • Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor which may recur locally and rarely causes metastases to vital organs.
  • DFSPs have specific chromosomal abnormalities involving the platelet-derived growth factor beta-chain locus (PDGFB) which may render these tumors responsive to targeted therapy with the tyrosine kinase inhibitor imatinib mesylate.
  • A patient with locally recurrent and metastatic DFSP resistant to first-line chemotherapy was treated with imatinib mesylate 400 mg/day.
  • Physical examination showed response within the first month of treatment, and subsequent computed tomography and fluorodeoxyglycose positron emission tomography documented complete response to imatinib therapy.
  • [MeSH-major] Dermatofibrosarcoma / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Benzamides. Chromosome Aberrations. Female. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Middle Aged. Mutation / genetics. Positron-Emission Tomography. Receptor, Platelet-Derived Growth Factor beta / genetics. Remission Induction

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746584.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


15. Murray PM: Soft tissue sarcoma of the upper extremity. Hand Clin; 2004 Aug;20(3):325-33, vii
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma of the upper extremity.
  • Soft tissue sarcomas of the upper extremities are rare and hand surgeons typically encounter only one or two undiagnosed soft tissue sarcomas during their careers.
  • It is incumbent on the physician to review repeatedly the characteristics of these tumors and remain suspicious, because these lesions typically are misdiagnosed and treatment is delayed.
  • The most common soft tissue sarcomas of the upper extremity are the epithelioid sarcoma, synovial cell sarcoma, and malignant fibrous histiocytoma.
  • Limb salvage surgery is the treatment of choice for soft tissue sarcomas to preserve upper extremity function.
  • Following wide tumor resection, adjuvant therapies such as chemotherapy, external beam radiation therapy, and brachytherapy may lessen local recurrence rates, but their effect on overall survival remains unclear.
  • [MeSH-major] Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Arm. Biopsy. Chemotherapy, Adjuvant. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / mortality. Histiocytoma, Benign Fibrous / pathology. Humans. Liposarcoma / pathology. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Synovial / diagnosis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15275691.001).
  • [ISSN] 0749-0712
  • [Journal-full-title] Hand clinics
  • [ISO-abbreviation] Hand Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


16. Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A: Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs; 2006 Nov;17(10):1223-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
  • Dermatofibrosarcoma protuberans is a soft-tissue tumor that may recur locally and rarely causes metastases to vital organs.
  • Dermatofibrosarcoma protuberans has specific chromosomal abnormalities involving the platelet-derived growth factor beta-chain locus that may render these tumors responsive to targeted therapy with the tyrosine kinase inhibitor imatinib mesylate.
  • A patient with locally recurrent and metastatic dermatofibrosarcoma protuberans who had already undergone surgery 22 times was initially treated with imatinib mesylate 400 mg/day.
  • The treatment dose was increased after 7 days to 400 mg twice daily.
  • The patient was followed up for response and toxicity by physical examination and imaging studies, comprising computed tomography and fluorodeoxyglucose positron emission tomography.
  • Clinical response could be demonstrated after the first month of treatment, and subsequent computed tomography and positron emission tomography documented a response to imatinib mesylate therapy.
  • We conclude that antitumor activity of metastatic dermatofibrosarcoma protuberans can be obtained with imatinib mesylate treatment with minimal side-effects.
  • [MeSH-major] Dermatofibrosarcoma / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Scalp. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Humans. Imatinib Mesylate. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075323.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


17. Luo Y, Chen ZD, Hu BQ: [The analysis of different treatment methods for 184 cases of soft tissue sarcoma]. Zhonghua Zhong Liu Za Zhi; 2004 Aug;26(8):502-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis of different treatment methods for 184 cases of soft tissue sarcoma].
  • OBJECTIVE: To study the proper way of using combined postoperative chemo-radiotherapy and prognostic factors of soft tissue sarcoma.
  • These patients were devided into surgery group (S, 94 patients), surgery plus postoperative radiotherapy group (S + R, 62 patients) and surgery plus chemotherapy group (S + C, 28 patients).
  • Clinical stage, pathological type and therapeutic method were also important prognostic factors for the long term survival.
  • CONCLUSION: Surgery plus postoperative radiotherapy can improve the 5-year survival rate of soft tissue sarcoma.
  • [MeSH-major] Dermatofibrosarcoma / therapy. Skin Neoplasms / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Liposarcoma / mortality. Liposarcoma / secondary. Liposarcoma / therapy. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retroperitoneal Neoplasms / mortality. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / therapy. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15555345.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Verweij J, Baker LH: Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer; 2010 Mar;46(5):863-8
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations.
  • Soft tissue sarcomas, although sharing a mesenchymal origin, are a heterogeneous group of diseases.
  • Genetic profiling studies have indicated that some soft tissue sarcoma subtypes, despite a distinct histo-pathological difference, may be closely related.
  • Molecular biology research in addition has identified several subtype-specific oncogenes and their protein products that could serve as treatment targets.
  • Since many of the new molecularly targeted agents do not induce tumour regression, but mainly result in growth inhibition, it is therefore necessary also to change the study end-point in screening studies in the search for active treatments.
  • In view of all these it is proposed to consider using alternative end-points such as progression-free rates at pre-set times, or progression arrest at first evaluation.
  • Soft tissue sarcoma treatment and research will require a change of approach and necessitate global cooperation.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Cytotoxins / therapeutic use. Sarcoma
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Benzamides. Dermatofibrosarcoma / drug therapy. Dermatofibrosarcoma / genetics. Disease Progression. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / genetics. Hemangioendothelioma / drug therapy. Hemangioendothelioma / genetics. Hemangiosarcoma / drug therapy. Hemangiosarcoma / genetics. Humans. Imatinib Mesylate. Leiomyosarcoma / drug therapy. Leiomyosarcoma / genetics. Liposarcoma, Myxoid / drug therapy. Liposarcoma, Myxoid / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Research Design. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / genetics. Skin Neoplasms / drug therapy. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138507.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cytotoxins; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 62
  •  go-up   go-down


19. Penel N, Van Haverbeke C, Lartigau E, Vilain MO, Ton Van J, Mallet Y, Lefebvre JL: Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach. Oral Oncol; 2004 Oct;40(9):890-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach.
  • Adult head and neck soft tissue sarcomas (AHNSTS) are rare, and data concerning treatment results are spare.
  • Aggressive fibromatosis, dermatofibrosarcoma, Kaposi sarcoma, chondrosarcoma and osteogenic sarcoma were excluded.
  • Associated treatments were neoadjuvant chemotherapy, adjuvant chemotherapy and postoperative radiotherapy in respectively, 4, 3 and 10 cases.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15380166.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


20. Alaggio R, Ninfo V, Rosolen A, Coffin CM: Primitive myxoid mesenchymal tumor of infancy: a clinicopathologic report of 6 cases. Am J Surg Pathol; 2006 Mar;30(3):388-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue sarcomas in the first year of life are rare, and the most common sarcomas in infancy are embryonal rhabdomyosarcoma, Ewing sarcoma/primitive neuroectodermal tumor, congenital infantile fibrosarcoma, and primitive sarcomas such as undifferentiated sarcoma.
  • PMMTI occurred in 6 infants, 3 of whom had a congenital presentation of a soft tissue mass.
  • Three patients had recurrences or metastasis treated with a combination of surgery and chemotherapy.
  • One patient is alive with persistent locally aggressive disease, 2 are alive with no evidence of recurrence, 1 had a recurrence treated surgically without further follow-up information, 1 patient died with persistent tumor and sepsis 6 weeks after diagnosis, and 1 patient was lost to follow-up.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / pathology. Nerve Sheath Neoplasms / pathology. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538060.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETV6-NTRK3 fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


21. Blaise G, Nikkels AF, Quatresooz P, Hermanns-Lê T, Piérard GE: Childhood cutaneous leiomyosarcoma. Pediatr Dermatol; 2009 Jul-Aug;26(4):477-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous leiomyosarcoma is a soft tissue neoplasm exhibiting an aggressive local behavior and a potential for distant metastases.
  • It is rare during childhood and diagnosis can be challenging both clinically and histologically.
  • Surgical excision with wide lateral and deep margins is the treatment of choice, whereas radiotherapy and chemotherapy are contraindicated.
  • [MeSH-minor] Child. Dermatofibrosarcoma / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Microscopy, Electron. Skin Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689533.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sagar TG, Chandra A, Raman SG, Swaminathan R: Paucity of hematological neoplasia after treatment of Hodgkin disease: observation after long-term follow-up at Cancer Institute, Chennai, south India. Pediatr Hematol Oncol; 2002 Apr-May;19(3):197-203
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paucity of hematological neoplasia after treatment of Hodgkin disease: observation after long-term follow-up at Cancer Institute, Chennai, south India.
  • The purpose of the study was to evaluate the incidence of second malignancies in childhood Hodgkin disease treated with COPP and COPP/ABV (replacing mechlorethamine by cyclophosphamide) chemotherapy.
  • All 5 were solid tumors: one each of soft tissue sarcoma, dermatofibrosarcoma, micropapillary carcinoma of thyroid, malignant phylloides tumor of breast, and chondrosarcoma of ilium.
  • All patients had received combination chemotherapy and radiotherapy.
  • All these patients had advanced stage of cancer and were 7-14 years of age at the time of diagnosis of first primary Hodgkin disease.
  • COPP and COPP/ABV are effective therapeutic regimens.
  • The paucity of secondary hematological malignancies is unique in this series and may be attributed to the substitution of nitrogen mustard with cyclophosphamide in the chemotherapy combination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hematologic Neoplasms / chemically induced. Hodgkin Disease / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Child, Preschool. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / prevention & control. Prednisone / administration & dosage. Procarbazine / administration & dosage. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11936733.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVPPABO protocol
  •  go-up   go-down


23. Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA: Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol; 2007 Jun;8(6):513-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opportunities for improving the therapeutic ratio for patients with sarcoma.
  • Limb-sparing surgery delivered at specialised sarcoma centres as part of a multidisciplinary approach has become the standard treatment for most patients and usually provides excellent local control.
  • Preoperative treatment with chemotherapy is most common for patients with bone sarcomas.
  • The ideal sequence of surgery and radiation for local management of soft-tissue sarcoma remains controversial on the basis of early versus late treatment complications, although preoperative radiation can provide the best results for improved long-term function.
  • However, metastatic disease is common, and conventional chemotherapy provides for only a narrow therapeutic window outside of a few responsive pathological subtypes.
  • Targeting underlying molecular events in specific sarcomas can provide for dramatic benefits, as has been seen with imatinib treatment for gastrointestinal stromal tumours and dermatofibrosarcoma protuberans.
  • Trials of agents targeting the cell cycle and angiogenesis in soft-tissue sarcomas, and of those targeting osteoclasts in bone sarcomas, are currently underway.
  • Research in stem-cell biology and nanotechnology holds promise for additional novel treatment options in the future.
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Aug;8(8):667-8; author reply 668-9 [17679078.001]
  • [ErratumIn] Lancet Oncol. 2007 Aug;8(8):670
  • (PMID = 17540303.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


24. Tuveson DA, Fletcher JA: Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol; 2001 Jul;13(4):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signal transduction pathways in sarcoma as targets for therapeutic intervention.
  • A large group of these genes participate in signal transduction pathways and represent potential sites of disease intervention with targeted therapies.
  • This review will discuss five types of sarcoma that display aberrant tyrosine kinase pathway signaling: gastrointestinal stromal tumor, inflammatory myofibroblastic tumor, congenital fibrosarcoma and mesoblastic nephroma, dermatofibrosarcoma protuberans, and desmoplastic small round cell tumor; one sarcoma predisposition syndrome with specific dysregulation of the ras pathway--neurofibromatosis--will also be discussed.
  • [MeSH-major] Signal Transduction. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Protein-Tyrosine Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11429482.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 80
  •  go-up   go-down






Advertisement